StockNews.AI
ATXS
StockNews.AI
62 days

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

1. Astria Therapeutics will participate at the Oppenheimer I&I Summit in June. 2. CEO Jill C. Milne will discuss advances in dermatology therapies. 3. The company is developing therapies for allergic and immunologic diseases. 4. Navenibart (STAR-0215) targets hereditary angioedema treatment. 5. STAR-0310 aims to treat atopic dermatitis.

3m saved
Insight
Article

FAQ

Why Bullish?

Participation in prominent summits can enhance investor confidence, similar to past biotech success during conferences.

How important is it?

The summit participation highlights ATXS's commitment to innovation in critical therapy areas.

Why Short Term?

Immediate interest may surge from the summit discussion, leading to short-term gains.

Related Companies

VRTXREGNAMGN
- BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit on June 25 in New York, NY. Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a panel titled, “Advances in Dermatology: AD and CSU” on Wednesday, June 25 at 10:45am ET. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. More News From Astria Therapeutics, Inc.

Related News